Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI

COPD Clinical Trial

— COPD  

Official title:

Effects of Glycopyrrolate/Formoterol (Bevespi) on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03324607
• Other study ID #: Pro00086693
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: April 20, 2018
• Est. completion date: November 12, 2019

Study information

• Verified date: December 2020
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the new inhaler, Bevespi improves lung function. Magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas, that can provide useful images of the functioning of the lung will be used as a new measure to determine change in function. The investigator anticipate these images will provide more specific information about lung disease than standard lung function tests in response to treatment.

Description:

The study will characterize ventilation and gas transfer distributions in GOLD II and III COPD patients and assess the potential for these physiological parameters as a novel phenotyping method using Magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas.

The study will additionally quantify regional ventilation and gas transfer response to glycopyrrolate/formoterol in GOLD II and III COPD patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: November 12, 2019
• Est. primary completion date: November 12, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Clinical diagnosis of COPD confirmed by post-bronchodilator spirometry demonstrating (forced expiratory volume at 1 second(FEV1)/forced vital capacity (FVC) < 0.70 and forced expiratory volume at 1 second (FEV1) in GOLD 2 or 3 stage (30%= (forced expiratory volume at 1 second [FEV1] < 80%)

• Willing and able to give informed consent and adhere to visit/protocol schedules

• Women of childbearing potential must have a negative urine pregnancy test

Exclusion Criteria:

• Upper respiratory tract infection within 6 weeks

• Chronic systemic corticosteroid use > 10 mg/day of prednisone

• Chronic oxygen use (intermittent or continuous)

• Previous lung resection surgery or decortication

• Previous history of pneumothorax

• Evidence of interstitial, occupational or chronic infectious lung disease by imaging studies

• History of exposure to occupational or environmental hazards that are known to cause lung diseases

• For women of child bearing potential, positive pregnancy test

• Major chronic illnesses which in the judgement of the study physician would interfere with participation in the study

• Patients who are not willing to withhold COPD inhalers for the run-in period.

• MRI is contraindicated based on responses to MRI screening questionnaire

• Subject is pregnant or lactating

• Respiratory illness of a bacterial or viral etiology within 30 days of MRI

• Subject has any form of known cardiac arrhythmia

• Subject does not fit into 129Xe vest coil used for MRI

• Subject cannot hold his/her breath for 15 seconds

• Subject deemed unlikely to be able to comply with instructions during imaging

Related Conditions & MeSH terms

• Congenital Abnormalities
• COPD

Intervention

Drug:
• hyperpolarized 129Xe gas MRI
There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi. Images obtained using 129Xe MRI will be compared with standard lung function tests that are used routinely in the clinic, 6 minute walk test that assesses walking ability and several questionnaires that assess shortness of breath and life quality.
• Bevespi Aerosphere
There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi.

Locations

Country	Name	City	State
United States	Duke Asthma, Allergy, and Airway Center	Durham	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Bastiaan Driehuys

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ventilation Distribution as Measured by Ventilation Defect+Low Percent	The ventilation distribution as measured by ventilation defect+low percent is to measure the area of the lung that has no air.	Week 2
Primary	Barrier Uptake.	Diffusion of Xe gas across the lung membrane into the blood. This measures how well oxygen goes through the lung into the blood.	2 weeks
Primary	Red Blood Cell (RBC) Uptake	Amount of Xe gas that enters the blood stream after it diffuses across the lung membrane	2 weeks
Secondary	Pulmonary Function Test - Forced Vital Capacity (FVC)	Forced vital capacity (FVC) is the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible, as measured by spirometry.	2 weeks
Secondary	Pulmonary Function Test - Forced Expiratory Volume-one Second (FEV1)	FEV1 is a lung airflow measure to assess the amount of air that can be blown out in one second.	2 weeks
Secondary	Pulmonary Function Test - Total Lung Capacity (TLC)	Total Lung Capacity (TLC) is the volume in the lungs at a maximal inhalation.	2 weeks
Secondary	Pulmonary Function Test - Residual Volume (RV)	Residual volume (RV) is the volume of air remaining in the lungs after a maximal exhalation.	2 weeks
Secondary	Pulmonary Function Test - Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)	DLCO measures the ability of oxygen to travel from the air sacs of the lungs to the blood stream.	2 weeks
Secondary	6-minute Walk Test (6MWT)	The 6-minute walk test (6MWT) measures the distance walked at a natural pace for 6 minutes.	2 weeks
Secondary	St. George's Respiratory Questionnaire (SGRQ) Score	The SGRQ is used to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating more limitations.	2 weeks
Secondary	Rating of Perceived Dyspnea (RPD) Scale	A patient reported outcome to measure perceived exertion during physical activity. The RPD scale goes from 0 to 10, where 0 = no shortness of breath at all and 10 = maximal shortness of breath (needing to stop the exercise or activity).	2 weeks
Secondary	COPD Assessment Test (CAT) Score	Functional measurement for COPD patients. Range of CAT scores from 0-40. Higher scores denote a more severe impact of COPD on a patient's life.	2 weeks